FibroGen Q4 2023 GAAP EPS $(0.57) Misses $(0.42) Estimate, Sales $27.14M Miss $38.90M Estimate
Portfolio Pulse from Benzinga Newsdesk
FibroGen (NASDAQ:FGEN) reported Q4 2023 GAAP EPS of $(0.57), missing the $(0.42) estimate, with sales of $27.14M also missing the $38.90M estimate. This represents a 21.04% decrease in sales compared to the same period last year.
February 26, 2024 | 9:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
FibroGen reported a significant miss in both EPS and sales for Q4 2023, with a notable year-over-year decrease in sales.
Missing both EPS and sales estimates significantly, especially with a year-over-year decrease in sales, is likely to negatively impact investor sentiment and could lead to a short-term decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100